Daclatasvir: A Review of Its Use in Adult Patients with Chronic Hepatitis C Virus Infection

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides

(2014) Tomomi Furihata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

(2014) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

(2014) Fiona McPhee et al.   ANTIVIRAL THERAPY

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection

(2014) Fumitaka Suzuki et al.   ANTIVIRAL THERAPY

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1

(2014) Namiki Izumi et al.   ANTIVIRAL THERAPY

Global distribution and prevalence of hepatitis C virus genotypes

(2014) Jane P. Messina et al.   HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2014

(2014)   JOURNAL OF HEPATOLOGY

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Network meta-analysis of direct-acting antivirals in combination with peginterferon–ribavirin for previously untreated patients with hepatitis C genotype 1 infection

(2014) E. Druyts et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

(2013) Marc Bifano et al.   ANTIVIRAL THERAPY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2013)   JOURNAL OF HEPATOLOGY

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

(2012) Lenore A. Pelosi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL

(2012) V. Ratziu et al.   JOURNAL OF HEPATOLOGY

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

(2012) M. Michele Manos et al.   JOURNAL OF MEDICAL VIROLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

An overview of HCV molecular biology, replication and immune responses

(2011) Usman A Ashfaq et al.   Virology Journal

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE